{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"13"},{"groupId":"BG007","value":"48"},{"groupId":"BG008","value":"54"},{"groupId":"BG009","value":"163"},{"groupId":"BG010","value":"71"},{"groupId":"BG011","value":"400"}],"units":"Participants"}],"groups":[{"description":"Patients received tazemetostat 100 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"BG000","title":"Phase 1: Tazemetostat 100 mg"},{"description":"Patients received tazemetostat 200 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent","id":"BG001","title":"Phase 1: Tazemetostat 200 mg"},{"description":"Patients received tazemetostat 400 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"BG002","title":"Phase 1: Tazemetostat 400 mg"},{"description":"Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent","id":"BG003","title":"Phase 1: Tazemetostat 800 mg"},{"description":"Patients received tazemetostat 1600 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"BG004","title":"Phase 1: Tazemetostat 1600 mg"},{"description":"Patients received tazemetostat 200 mg as a single oral dose on Day -8 either after fasting for 8 hours before dosing or immediately after consuming a high-fat breakfast on Day -8. Following a 7-day washout period, patients crossed over to receive the second tazemetostat 200 mg single oral dose on Day -1 in the opposite condition (fed or fasted).","id":"BG005","title":"Phase 1: Food Effect (All Patients)"},{"description":"Patients received tazemetostat 800 mg orally BID continuously starting on Day 1, with a single oral dose of midazolam 2 mg administered on Day -1 and then on Day 15. Post Day 15, patients continued to receive tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.","id":"BG006","title":"Phase 1: Tazemetostat 800 mg + Midazolam 2 mg"},{"description":"Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.\n\nTazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.","id":"BG007","title":"Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2"},{"description":"Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.\n\nTazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.","id":"BG008","title":"Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2"},{"description":"Patients with R/R DLBCL received 800 mg of tazemetostat monotherapy, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.\n\nTazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.","id":"BG009","title":"Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy"},{"description":"Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. In addition, these patients also received prednisolone 40 mg/m\\^2 on Days 1 to 5 and 15 to 19 from Cycle 1 to Cycle 4 post which tazemetostat monotherapy was continued.","id":"BG010","title":"Phase 2 Group 4: Tazemetostat + Prednisolone in R/R DLBCL Combination Therapy"},{"description":"Total of all reporting groups","id":"BG011","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.74","value":"51.5"},{"groupId":"BG001","spread":"30.20","value":"55.0"},{"groupId":"BG002","spread":"7.00","value":"59.0"},{"groupId":"BG003","spread":"13.54","value":"56.4"},{"groupId":"BG004","spread":"21.42","value":"51.6"},{"groupId":"BG005","spread":"16.39","value":"53.2"},{"groupId":"BG006","spread":"13.66","value":"55.0"},{"groupId":"BG007","spread":"8.83","value":"62.0"},{"groupId":"BG008","spread":"11.38","value":"61.1"},{"groupId":"BG009","spread":"14.35","value":"63.2"},{"groupId":"BG010","spread":"11.78","value":"65.4"},{"groupId":"BG011","spread":"13.7","value":"61.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"26"},{"groupId":"BG008","value":"20"},{"groupId":"BG009","value":"72"},{"groupId":"BG010","value":"32"},{"groupId":"BG011","value":"176"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"22"},{"groupId":"BG008","value":"34"},{"groupId":"BG009","value":"91"},{"groupId":"BG010","value":"39"},{"groupId":"BG011","value":"224"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"7"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"38"},{"groupId":"BG008","value":"26"},{"groupId":"BG009","value":"103"},{"groupId":"BG010","value":"62"},{"groupId":"BG011","value":"268"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"25"},{"groupId":"BG009","value":"57"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"125"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"11"},{"groupId":"BG007","value":"33"},{"groupId":"BG008","value":"15"},{"groupId":"BG009","value":"71"},{"groupId":"BG010","value":"28"},{"groupId":"BG011","value":"186"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"15"},{"groupId":"BG008","value":"38"},{"groupId":"BG009","value":"89"},{"groupId":"BG010","value":"41"},{"groupId":"BG011","value":"208"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}